Table 3 Patients characteristics in both groups.

From: Significance of platinum distribution to predict platinum resistance in ovarian cancer after platinum treatment in neoadjuvant chemotherapy

 

Type A (n = 16)

Type B (n = 11)

p-value

Age at diagnosis, years (median, range)

61.5 (41–75)

60.0 (41–71)

0.394

NAC course, times (median, range)

5.5 (3–9)

6.0 (3–10)

0.121

Duration from NAC to IDS, days (median, range)

35.0 (23–50)

36.0 (24–53)

0.645

CA125 at diagnosis, U/mL (median, range)

3208 (161–17,434)

1640 (142–6220)

0.368

CA125 presurgery, U/mL (median, range)

58.6 (8.2–587)

15.0 (11–34)

0.023

Complete surgery (number, %)

10/16 (62.5%)

8/11 (72.7%)

0.692

Tumor regression rate, % (median, range)

50 (10–90)

70 (30–95)

0.029

  1. NAC neo-adjuvant chemotherapy, IDS interval-debulking surgery.